Mechanisms of Allergen-Specific Immunotherapy and Novel Ways for Vaccine Development
Open Access
- 1 January 2013
- journal article
- review article
- Published by Japanese Society of Allergology in Allergology International
- Vol. 62 (4), 425-433
- https://doi.org/10.2332/allergolint.13-rai-0608
Abstract
Allergen-specific immunotherapy (SIT) is the only available curative treatment of allergic diseases. Recent evidence provided a plausible explanation to its multiple mechanisms inducing both rapid desensitization and long-term allergen-specific immune tolerance, and suppression of allergic inflammation in the affected tissues. During SIT, peripheral tolerance is induced by the generation of allergen-specific regulatory T cells, which suppress proliferative and cytokine responses against the allergen of interest. Regulatory T cells are characterized by IL-10 and TGF-beta secretion and expression of important cell surface suppressive molecules such as cytotoxic T lymphocyte antigen-4 and programmed death-1 that directly or indirectly influence effector cells of allergic inflammation, such as mast cells, basophils and eosinophils. Regulatory T cells and particularly IL-10 also have an influence on B cells, suppressing IgE production and inducing the production of blocking type IgG4 antibodies. In addition, development of allergen-specific B regulatory cells that produce IL-10 and develop into IgG4 producing plasma cells represent essential players in peripheral tolerance. These findings together with the new biotechnological approaches create a platform for development of the advanced vaccines. Moreover, reliable biomarkers could be selected and validated with the intention to select the patients who will benefit most from this immune-modifying treatment. Thus, allergen-SIT could provide a complete cure for a larger number of allergic patients and novel preventive approaches need to be elaboratedKeywords
This publication has 80 references indexed in Scilit:
- Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus reportJournal of Allergy and Clinical Immunology, 2013
- Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & ImmunologyJournal of Allergy and Clinical Immunology, 2013
- Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needsJournal of Allergy and Clinical Immunology, 2012
- Untangling asthma phenotypes and endotypesAllergy, 2012
- Therapies for allergic inflammation: refining strategies to induce toleranceNature Medicine, 2012
- Allergens and their role in the allergic immune responseImmunological Reviews, 2011
- Asthma endotypes: A new approach to classification of disease entities within the asthma syndromeJournal of Allergy and Clinical Immunology, 2011
- Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tabletJournal of Allergy and Clinical Immunology, 2010
- Therapeutic manipulation of immune tolerance in allergic diseaseNature Reviews Drug Discovery, 2009
- In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposureThe Journal of Experimental Medicine, 2008